Business Context and Reporting Period
Company: Neuronetics, Inc. (Ticker: STIM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Neuronetics is a global leader in neuroscience, primarily known for the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation (TMS) device for treating major depressive disorder (MDD). Effective December 9, 2024, the Company completed the acquisition of Greenbrook TMS Inc., a leading provider of mental healthcare services operating 95 treatment centers in the U.S. This transaction vertically integrated Neuronetics, adding direct clinic revenue from TMS and SPRAVATO (esketamine) treatments to its existing capital equipment and treatment session sales model.
Key Financial Metrics
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Total Revenues | $74.9 | $71.3 |
| Gross Profit | $54.2 | $51.7 |
| Gross Margin | 72.3% | 72.5% |
| Net Loss | $(43.7) | $(30.2) |
| Operating Loss | $(34.6) | $(30.6) |
| Cash and Cash Equivalents (Year End) | $18.5 | $59.7 |
| Long-Term Debt (Net) | $55.2 | $59.3 |
| Accumulated Deficit | $(419.8) | $(376.1) |
Revenue Composition (2024): U.S. revenues accounted for 97% of total revenue ($72.5M). Within U.S. revenues, treatment sessions represented 70%, NeuroStar system sales 21%, and clinic revenue (from Greenbrook) 6%. International revenue was $2.4M (3%).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% year-over-year, driven by the inclusion of Greenbrook clinic revenue and a 19% increase in international revenue. However, NeuroStar system unit sales in the U.S. declined 7% (from 204 to 185 units).
- Profitability: Net loss widened by 45% to $43.7M. This was primarily due to a $4.4M loss on debt extinguishment, a $4.0M software impairment charge in R&D, and increased General and Administrative (G&A) expenses of $4.9M (19% increase) related to acquisition costs.
- Debt Restructuring: In July 2024, the Company replaced its previous $60M credit facility with SLR Investment Corp. (Solar) with a new $90M facility with Perceptive Credit Holdings IV, LP. The Company borrowed $60M under the new facility to pay off the Solar debt, incurring a $4.4M loss on extinguishment.
- Acquisition Impact: The Greenbrook acquisition contributed approximately $4.4M in revenue and $1.7M in net loss for the period from December 9 to December 31, 2024. The purchase price was $38.8M, allocated to $18.6M in goodwill and $19.7M in intangible assets.
Guidance, Outlook, and Risks
Management Outlook:
- The Company expects to achieve cash flow break-even in the third quarter of 2025.
- Management anticipates continued operating losses in the near term as it integrates Greenbrook and expands sales and marketing initiatives.
- Strategy focuses on increasing patient utilization at existing sites, expanding the Greenbrook treatment center network, and optimizing the sales force.
Key Risks and Contingencies:
- Liquidity: Cash balances decreased significantly from $59.7M to $18.5M during 2024. The Company relies on its credit facility and anticipated revenues to fund operations. A secondary public offering in February 2025 raised approximately $18.9M.
- Debt Covenants: The Perceptive Facility includes a minimum net revenue covenant and a minimum liquidity covenant. Failure to comply could result in default and acceleration of debt repayment.
- Reimbursement and Billing: The Company faces risks related to third-party payor reimbursement rates and billing complexities. Medicare Administrative Contractors have alleged approximately $1.2M in reimbursements may be subject to recoupment.
- Integration: Significant demands have been placed on management to integrate Greenbrook. Billing issues were discovered shortly after closing regarding patient responsibility payments, which the Company is addressing.
- Stock Listing: The Company received a notice from Nasdaq in October 2024 regarding failure to meet the minimum bid price requirement but regained compliance in November 2024.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.5M year-end cash balance plus the $18.9M raised in February 2025 to fund operations until the projected Q3 2025 cash flow break-even.
- Debt Covenant Compliance: Monitor quarterly reports for compliance with the Perceptive Facility's minimum net revenue and liquidity covenants.
- Greenbrook Integration: Assess the resolution of billing and revenue cycle management issues identified post-acquisition and the realization of anticipated synergies.
- Reimbursement Audits: Track the status of the $1.2M potential recoupment from Medicare and any other government audits.
- Unit Sales Trends: Monitor the decline in NeuroStar system unit sales (down 7% in 2024) to determine if the shift to clinic-based revenue is offsetting capital equipment sales.